Dr. Alexander Kretschmer on next steps for ExoDx Prostate test

Dr. Alexander Kretschmer, MD, discusses the next steps with research and clinical use of the ExoDx Prostate test (EPI test). The non-invasive, urine-based genomic test is a risk assessment tool that helps physicians and patients determine whether a prostate biopsy is necessary when PSA screening provides an ambiguous result

Kretschmer is an assistant professor of Urology at Ludwig-Maximilians-University Munich.